Companies Dominating the Aspergillosis Treatment Market
- Bayer AG
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- WOT Analysis
- Mayne Pharma Group Limited
- PULMATRiX Inc.
- Endo International plc
- Johnson & Johnson Services Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Abbott
- Takeda Pharmaceutical Company Limited
Browse Key Market Insights with Data Illustration:
In the News
- Endo International plc released of the first generic Noxafil (posaconazole) Injection marks a substantial growth in the aspergillosis treatment market. This generic posaconazole injection is particularly created to identify invasive aspergillosis in patients aged 13 and above, surrounding both adults and pediatric populations.Candida infections in clients who are at significant risk of creating these infections because of being seriously immunocompromised, like hematopoietic stem cell transplant (HSCT) payees with graft-versus-host disease (GVHD) or those with hematologic enmities with extended neutropenia (low white blood cell counts) from chemotherapy.
- Mayne Pharma Group Limited got approval from U.S.FDA for TolsuraTM (SUBA-Itraconazole Capsules). TOLSURA is a novel itraconazole development implemented to cure systemic fungal infections like aspergillosis, blastomycosis, and histoplasmosis. Tolsura is suggested for the therapy of blastomycosis (pulmonary and extrapulmonary), histoplasmosis (involving chronic cavitary pulmonary disease and disseminated non-meningeal histoplasmosis), and aspergillosis (pulmonary and extrapulmonary, in sufferers who are weak or who are stubborn to amphotericin B therapy).
